“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...

A value stock is generally a company that trades at a price lower than its fundamental value or what its performance suggests ...

The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

GSK said it would receive $370 million as part of a U.S. patent settlement between CureVac and BioNTech related to messenger mRNA-based Covid-19 vaccines.

Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...